Prolactin decreases the expression ratio of receptor activator of nuclear factor κB ligand/osteoprotegerin in human fetal osteoblast cells

Cell Biology International

Volumn 32, Issue 9, 2008, Pages 1126-1135

  Seriwatanachai, Dutmanee ^a   Charoenphandhu, Narattaphol ^a   Suthiphongchai, Tuangporn ^a   Krishnamra, Nateetip ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Alkaline phosphatase; hFOB; OPG; Osteocalcin; PI3K; Prolactin receptor; RANKL

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ALKALINE PHOSPHATASE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROLACTIN; PROLACTIN RECEPTOR;

ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FETUS; HUMAN; HUMAN CELL; INCUBATION TIME; OSTEOBLAST; OSTEOLYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ALKALINE PHOSPHATASE; CELL PROLIFERATION; CELLS, CULTURED; CHROMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; FETUS; GENE EXPRESSION REGULATION; HUMANS; MORPHOLINES; OSTEOBLASTS; OSTEOCALCIN; OSTEOPROTEGERIN; PROLACTIN; RANK LIGAND; RECEPTORS, PROLACTIN; RNA, MESSENGER;

ANIMALIA; RATTUS;

EID: 49749096387     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2008.04.026     Document Type: Article

References (48)

1. Abdallah B.M., Stilgren L.S., Nissen N., Kassem M., Jorgensen H.R., and Abrahamsen B. Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures. Calcif Tissue Int 76 (2005) 90-97
2. Amaral M.E., Cunha D.A., Anhê G.F., Ueno M., Carneiro E.M., Velloso L.A., et al. Participation of prolactin receptors and phosphatidylinositol 3-kinase and MAP kinase pathways in the increase in pancreatic islet mass and sensitivity to glucose during pregnancy. J Endocrinol 183 (2004) 469-476
3. Bataille-Simoneau N., Gerland K., Chappard D., Basle M.F., and Mercier L. Expression of prolactin receptors in human osteosarcoma cells. Biochem Biophys Res Commun 229 (1996) 323-328
4. Biller B.M., Baum H.B., Rosenthal D.I., Saxe V.C., Charpie P.M., and Klibanski A. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 75 (1992) 692-697
5. Bishop J.D., Nien W.L., Dauphinee S.M., and Too C.K. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells. J Endocrinol 190 (2006) 307-312
6. Bole-Feysot C., Goffin V., Edery M., Binart N., and Kelly P.A. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 19 (1998) 225-268
7. Brixen K., Hansen T.B., Hauge E., Vahl N., Jorgensen J.O., Christiansen J.S., et al. Growth hormone treatment in adults with adult-onset growth hormone deficiency increases iliac crest trabecular bone turnover: a 1-year, double-blind, randomized, placebo-controlled study. J Bone Miner Res 15 (2000) 293-300
8. Cao J., Venton L., Sakata T., and Halloran B.P. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J Bone Miner Res 18 (2003) 270-277
9. Charoenphandhu N., and Krishnamra N. Prolactin is an important regulator of intestinal calcium transport. Can J Physiol Pharmacol 85 (2007) 569-581
10. Charoenphandhu N., Teerapornpuntakit J., Methawasin M., Wongdee K., Thongchote K., and Krishnamra N. Prolactin decreases expression of Runx2, osteoprotegerin and RANKL in primary osteoblasts derived from tibiae of adult female rats. Can J Physiol Pharmacol 86 (2008) 240-248
11. Charoenphandhu N., Wongdee K., Tudpor K., Pandaranandaka J., and Krishnamra N. Chronic metabolic acidosis upregulated claudin mRNA expression in the duodenal enterocytes of female rats. Life Sci 80 (2007) 1729-1737
12. Clément-Lacroix P., Ormandy C., Lepescheux L., Ammann P., Damotte D., Goffin V., et al. Osteoblasts are a new target for prolactin: analysis of bone formation in prolactin receptor knockout mice. Endocrinology 140 (1999) 96-105
13. Coss D., Yang L., Kuo C.B., Xu X., Luben R.A., and Walker A.M. Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am J Physiol Endocrinol Metab 279 (2000) E1216-E1225
14. Crosignani P.G. Current treatment issues in female hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 125 (2006) 152-164
15. Grimaud E., Soubigou L., Couillaud S., Coipeau P., Moreau A., Passuti N., et al. Receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 163 (2003) 2021-2031
16. Harris S.A., Enger R.J., Riggs B.L., and Spelsberg T.C. Development and characterization of a conditionally immortalized human fetal osteoblastic cell line. J Bone Miner Res 10 (1995) 178-186
17. Hoang Q.Q., Sicheri F., Howard A.J., and Yang D.S. Bone recognition mechanism of porcine osteocalcin from crystal structure. Nature 425 (2003) 977-980
18. Jantarajit W., Thongon N., Pandaranandaka J., Teerapornpuntakit J., Krishnamra N., and Charoenphandhu N. Prolactin-stimulated transepithelial calcium transport in duodenum and Caco-2 monolayer are mediated by the phosphoinositide 3-kinase pathway. Am J Physiol Endocrinol Metab 293 (2007) E372-E384
19. Kelly P.A., Binart N., Freemark M., Lucas B., Goffin V., and Bouchard B. Prolactin receptor signal transduction pathways and actions determined in prolactin receptor knockout mice. Biochem Soc Trans 29 (2001) 48-52
20. Kostenuik P.J. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5 (2005) 618-625
21. Krishnamra N., Lotinun S., and Limlomwongse L. Acute effect and mechanism of action of prolactin on the in situ passive calcium absorption in rat. Bone Miner 23 (1993) 253-266
22. 45Ca uptake, calcium deposit, and calcium resorption in weaned, young, and mature rats. Can J Physiol Pharmacol 74 (1996) 1157-1165
23. 45Ca accumulation in rats. Endocr J 44 (1997) 257-264
24. Landin-Wilhelmsen K., Nilsson A., Bosaeus I., and Bengtsson B.A. Growth hormone increases bone mineral content in postmenopausal osteoporosis: a randomized placebo-controlled trial. J Bone Miner Res 18 (2003) 393-405
25. Lotinun S., Limlomwongse L., and Krishnamra N. The study of a physiological significance of prolactin in the regulation of calcium metabolism during pregnancy and lactation in rats. Can J Physiol Pharmacol 76 (1998) 218-228
26. Lotinun S., Limlomwongse L., Sirikulchayanonta V., and Krishnamra N. Bone calcium turnover, formation, and resorption in bromocriptine- and prolactin-treated lactating rats. Endocrine 20 (2003) 163-170
27. Meaney A.M., Smith S., Howes O.D., O'Brien M., Murray R.M., and O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 184 (2004) 503-508
28. Mizuno A., Kanno T., Hoshi M., Shibata O., Yano K., Fujise N., et al. Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J Bone Miner Metab 20 (2002) 337-344
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
30. Mrak E., Villa I., Lanzi R., Losa M., Guidobono F., and Rubinacci A. Growth hormone stimulates osteoprotegerin expression and secretion in human osteoblast-like cells. J Endocrinol 192 (2007) 639-645
31. Owen T.A., Aronow M., Shalhoub V., Barone L.M., Wilming L., Tassinari M.S., et al. Progressive development of the rat osteoblast phenotype in vitro: reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. J Cell Physiol 143 (1990) 420-430
32. Parfitt A.M. Growth hormone and adult bone remodelling. Clin Endocrinol (Oxf) 35 (1991) 467-470
33. Piyabhan P., Krishnamra N., and Limlomwongse L. Changes in the regulation of calcium metabolism and bone calcium content during growth in the absence of endogenous prolactin and during hyperprolactinemia: a longitudinal study in male and female Wistar rats. Can J Physiol Pharmacol 78 (2000) 757-765
34. Prentice A. Calcium in pregnancy and lactation. Annu Rev Nutr 20 (2000) 249-272
35. Puntheeranurak S., Schreiber R., Spitzner M., Ousingsawat J., Krishnamra N., and Kunzelmann K. Control of ion transport in mouse proximal and distal colon by prolactin. Cell Physiol Biochem 19 (2007) 77-88
36. Ritchie L.D., Fung E.B., Halloran B.P., Turnlund J.R., Van Loan M.D., Cann C.E., et al. A longitudinal study of calcium homeostasis during human pregnancy and lactation and after resumption of menses. Am J Clin Nutr 67 (1998) 693-701
37. Schlemmer A., Johansen J.S., Pedersen S.A., Jorgensen J.O., Hassager C., and Christiansen C. The effect of growth hormone (GH) therapy on urinary pyridinoline cross-links in GH-deficient adults. Clin Endocrinol (Oxf) 35 (1991) 471-476
38. Seriwatanachai D., Thongchote K., Charoenphandhu N., Pandaranandaka J., Tudpor K., Teerapornpuntakit J., et al. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor κB ligand/osteoprotegerin ratio. Bone 42 (2008) 535-546
39. Sowa H., Kaji H., Yamaguchi T., Sugimoto T., and Chihara K. Smad3 promotes alkaline phosphatase activity and mineralization of osteoblastic MC3T3-E1 cells. J Bone Miner Res 17 (2002) 1190-1199
40. Stein G.S., Lian J.B., Stein J.L., Van Wijnen A.J., and Montecino M. Transcriptional control of osteoblast growth and differentiation. Physiol Rev 76 (1996) 593-629
41. Stilgren L.S., Rettmer E., Eriksen E.F., Hegedus L., Beck-Nielsen H., and Abrahamsen B. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-κB ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Bone 35 (2004) 256-265
42. Subramaniam M., Jalal S.M., Rickard D.J., Harris S.A., Bolander M.E., and Spelsberg T.C. Further characterization of human fetal osteoblastic hFOB 1.19 and hFOB/ERα cells: bone formation in vivo and karyotype analysis using multicolor fluorescent in situ hybridization. J Cell Biochem 87 (2002) 9-15
43. Thomas T., Gori F., Khosla S., Jensen M.D., Burguera B., and Riggs B.L. Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140 (1999) 1630-1638
44. Thongon N., Nakkrasae L.I., Thongbunchoo J., Krishnamra N., and Charoenphandhu N. Prolactin stimulates transepithelial calcium transport and modulates paracellular permselectivity in Caco-2 monolayer: Mediation by PKC and ROCK pathways. Am J Physiol Cell Physiol 294 (2008) C1158-C1168
45. Wang C., and Chan V. Divergent effects of prolactin on estrogen and progesterone production by granulosa cells of rat Graafian follicles. Endocrinology 110 (1982) 1085-1093
46. Wang C., Hsueh A.J., and Erickson G.F. Prolactin inhibition of estrogen production by cultured rat granulosa cells. Mol Cell Endocrinol 20 (1980) 135-144
47. Yamauchi T., Kaburagi Y., Ueki K., Tsuji Y., Stark G.R., Kerr I.M., et al. Growth hormone and prolactin stimulate tyrosine phosphorylation of insulin receptor substrate-1, -2, and -3, their association with p85 phosphatidylinositol 3-kinase (PI3-kinase), and concomitantly PI3-kinase activation via JAK2 kinase. J Biol Chem 273 (1998) 15719-15726
48. Yen M.L., Chien C.C., Chiu I.M., Huang H.I., Chen Y.C., Hu H.I., et al. Multilineage differentiation and characterization of the human fetal osteoblastic 1.19 cell line: a possible in vitro model of human mesenchymal progenitors. Stem Cells 25 (2007) 125-131